Rapport Therapeutics (RAPP) News Today $12.68 -0.32 (-2.46%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$12.68 0.00 (0.00%) As of 02/21/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Rapport Therapeutics (RAPP) Expected to Announce Earnings on ThursdayRapport Therapeutics (NASDAQ:RAPP) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22 at 1:55 AM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 8.5% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5% - Here's WhyFebruary 19 at 11:59 PM | marketbeat.comRapport Therapeutics, Inc. (RAPP)February 15, 2025 | ca.finance.yahoo.comRapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel NicolausFebruary 11, 2025 | markets.businessinsider.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Time to Buy?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Time to Buy?February 10, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% - Should You Sell?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% - Here's What HappenedFebruary 7, 2025 | marketbeat.comJennison Associates LLC Invests $1.11 Million in Rapport Therapeutics (NASDAQ:RAPP)Jennison Associates LLC bought a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 62,287 shares of the company's stock, valued at approximFebruary 7, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Short Interest UpdateRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a decline of 15.3% from the December 31st total of 1,770,000 shares. Currently, 8.6% of the company's stock are short sold. Based on an average daily volume of 104,700 shares, the days-to-cover ratio is presently 14.3 days.February 1, 2025 | marketbeat.comRapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on ThursdayRapport Therapeutics (NASDAQ:RAPP) will be releasing earnings on Thursday, February 6, Financial Modeling Prep reports.January 30, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 4.6% Higher - Still a Buy?Rapport Therapeutics (NASDAQ:RAPP) Shares Up 4.6% - Here's WhyJanuary 29, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Still a Buy?January 15, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month Low - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month Low - Time to Sell?January 14, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Here's WhyJanuary 13, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 6.9% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9% - What's Next?January 10, 2025 | marketbeat.comRapport Therapeutics’ Promising Trial Results and Leadership ChangeJanuary 10, 2025 | tipranks.comCORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS DisordersJanuary 9, 2025 | globenewswire.comRapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS DisordersJanuary 9, 2025 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week Low - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week Low - What's Next?January 8, 2025 | marketbeat.comGeode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP)Geode Capital Management LLC purchased a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 201,748 shares of the company's stock, valued at approximately $4,133,000.January 6, 2025 | marketbeat.comState Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP)State Street Corp acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,046 shares of the company's stock, valued at approximately $1,189,000. State StreeJanuary 3, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 4% - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4% - Should You Sell?December 31, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 4.6% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.6% - What's Next?December 19, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7% - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Trading Up 5.7% - Should You Buy?December 18, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP)Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 73,146 shares of the company's stock, valDecember 17, 2024 | marketbeat.comRapport Therapeutics management to meet with TruistDecember 6, 2024 | tipranks.comRapport Therapeutics presents data on long episode seizure biomarkerDecember 6, 2024 | tipranks.comRapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical SeizuresDecember 6, 2024 | globenewswire.comMaven Securities LTD Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP)Maven Securities LTD bought a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 29,930 shares of the company's stock, valDecember 5, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Purchased by Fmr LLCFmr LLC lifted its position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 10.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,486,468 shares of the company's stock after acquiring an additional 503December 5, 2024 | marketbeat.comRapport Therapeutics' Lock-Up Period Will Expire on December 4th (NASDAQ:RAPP)Rapport Therapeutics' (NASDAQ:RAPP - Get Free Report) lock-up period is set to end on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.November 27, 2024 | marketbeat.comLMR Partners LLP Reduces Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP)LMR Partners LLP lowered its holdings in Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 60.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the company's stock after selling 30,000 shares durNovember 20, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 6.5% - Here's WhyNovember 15, 2024 | marketbeat.comRapport Therapeutics to Present Data at American Epilepsy Society Annual MeetingNovember 14, 2024 | globenewswire.comRapport Therapeutics Reports Q3 Financials and Strategic UpdatesNovember 9, 2024 | tipranks.comRapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in NovemberNovember 4, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Here's What HappenedNovember 1, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 4.2% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.2% - Should You Sell?October 25, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Here's What HappenedOctober 21, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7% - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 2.7% - Time to Sell?October 18, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Hits New 52-Week High - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High - Time to Buy?October 16, 2024 | marketbeat.comMillennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)Millennium Management LLC acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 116,782 shares of the company's stock, vOctober 16, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Sees Significant Increase in Short InterestRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,840,000 shares, an increase of 32.4% from the September 15th total of 1,390,000 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is presently 11.6 days. Approximately 10.2% of the shares of the company are sold short.October 15, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next?October 14, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires Shares of 75,516 Rapport Therapeutics (NASDAQ:RAPP)The Manufacturers Life Insurance Company acquired a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,516 shares of the coOctober 11, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 4.1% Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.1%October 2, 2024 | marketbeat.comLogos Global Management LP Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP)Logos Global Management LP acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 208,910 shares of the company's stock, valued at approximately $4,859,000. Logos Global ManagemOctober 1, 2024 | marketbeat.comPerceptive Advisors LLC Invests $17.40 Million in Rapport Therapeutics (NASDAQ:RAPP)Perceptive Advisors LLC bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 748,183 shares of the company's stock, valued at approximately $17,403,000. Perceptive Advisors LLC owneSeptember 30, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Up 6.2%Rapport Therapeutics (NASDAQ:RAPP) Trading 6.2% HigherSeptember 27, 2024 | marketbeat.comARCH Venture Management LLC Makes New $86.73 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)ARCH Venture Management LLC bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 3,728,738 shares of the company's stock, valued at approximately $86,730,000. Rapport TheSeptember 24, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 2.4%Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 2.4%September 19, 2024 | marketbeat.com Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Media Mentions By Week RAPP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPP News Sentiment▼0.340.60▲Average Medical News Sentiment RAPP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPP Articles This Week▼22▲RAPP Articles Average Week Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTGX News Today MESO News Today CNTA News Today BHC News Today HRMY News Today CGON News Today TARS News Today JANX News Today AGIO News Today NAMS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
